(AXGN) Axogen - Ratings and Ratios
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US05463X1063
Nerve Graft, Connector, Protector, Cap
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 62.7% |
| Value at Risk 5%th | 85.4% |
| Relative Tail Risk | -17.16% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.56 |
| Alpha | 114.23 |
| CAGR/Max DD | 0.68 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.433 |
| Beta | 0.684 |
| Beta Downside | 0.803 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.03% |
| Mean DD | 22.26% |
| Median DD | 18.45% |
Description: AXGN Axogen October 24, 2025
Axogen Inc. (NASDAQ:AXGN) develops and commercializes a portfolio of biologically-derived devices for peripheral nerve regeneration, including the Avance Nerve Graft allograft, AxoGuard Nerve Connector, AxoGuard Nerve Protector (standard and HA+ versions), and AxoGuard Nerve Cap. These products are marketed to hospitals, surgery centers, military medical facilities, and specialists such as plastic, orthopedic, hand, oral, and maxillofacial surgeons, with the company headquartered in Alachua, Florida.
Key recent metrics: FY 2023 revenue reached approximately $71 million, driven primarily by a 38 % year-over-year increase in Avance graft sales; the company posted a net loss of $28 million, reflecting ongoing R&D and commercial expansion expenses. The peripheral nerve repair market is projected to grow at a CAGR of ~7 % through 2030, buoyed by an aging population, rising trauma incidence, and expanding reimbursement coverage for biologic nerve conduits. Axogen’s reliance on a single-source, processed human allograft (Avance) creates a supply-chain risk that could be mitigated by scaling its porcine-derived product lines.
For a deeper, data-driven view of AXGN’s valuation and risk profile, you might explore the analyst tools on ValueRay to see how these drivers are reflected in the model.
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-2.10m TTM) > 0 and > 6% of Revenue (6% = 12.9m TTM) |
| FCFTA 0.01 (>2.0%) and ΔFCFTA 6.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 40.26% (prev 34.96%; Δ 5.31pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.03 (>3.0%) and CFO 6.51m > Net Income -2.10m (YES >=105%, WARN >=100%) |
| Net Debt (-4.15m) to EBITDA (21.5m) ratio: -0.19 <= 3.0 (WARN <= 3.5) |
| Current Ratio 4.09 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (45.9m) change vs 12m ago 4.61% (target <= -2.0% for YES) |
| Gross Margin 74.76% (prev 76.40%; Δ -1.63pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 105.2% (prev 94.20%; Δ 10.95pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.87 (EBITDA TTM 21.5m / Interest Expense TTM 16.2m) >= 6 (WARN >= 3) |
Altman Z'' -4.56
| (A) 0.40 = (Total Current Assets 114.5m - Total Current Liabilities 28.0m) / Total Assets 216.4m |
| (B) -1.36 = Retained Earnings (Balance) -293.8m / Total Assets 216.4m |
| warn (B) unusual magnitude: -1.36 — check mapping/units |
| (C) 0.07 = EBIT TTM 14.1m / Avg Total Assets 204.2m |
| (D) -3.07 = Book Value of Equity -293.3m / Total Liabilities 95.6m |
| Total Rating: -4.56 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.24
| 1. Piotroski 3.50pt |
| 2. FCF Yield 0.22% |
| 3. FCF Margin 1.33% |
| 4. Debt/Equity 0.16 |
| 5. Debt/Ebitda -0.19 |
| 6. ROIC - WACC (= -1.35)% |
| 7. RoE -1.90% |
| 8. Rev. Trend 97.99% |
| 9. EPS Trend 79.34% |
What is the price of AXGN shares?
As of December 05, 2025, the stock is trading at USD 32.86 with a total of 3,148,141 shares traded.
Over the past week, the price has changed by +14.68%, over one month by +38.22%, over three months by +113.34% and over the past year by +121.54%.
Over the past week, the price has changed by +14.68%, over one month by +38.22%, over three months by +113.34% and over the past year by +121.54%.
Is AXGN a buy, sell or hold?
Axogen has received a consensus analysts rating of 4.71.
Therefore, it is recommended to buy AXGN.
- Strong Buy: 5
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AXGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 30.3 | -7.7% |
| Analysts Target Price | 30.3 | -7.7% |
| ValueRay Target Price | 32.2 | -2.1% |
AXGN Fundamental Data Overview December 02, 2025
Market Cap USD = 1.32b (1.32b USD * 1.0 USD.USD)
P/E Forward = 71.4286
P/S = 6.1286
P/B = 10.9383
Beta = 1.085
Revenue TTM = 214.7m USD
EBIT TTM = 14.1m USD
EBITDA TTM = 21.5m USD
Long Term Debt = 48.2m USD (from longTermDebt, last quarter)
Short Term Debt = 2.34m USD (from shortTermDebt, last quarter)
Debt = 19.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -4.15m USD (from netDebt column, last quarter)
Enterprise Value = 1.31b USD (1.32b + Debt 19.8m - CCE 23.9m)
Interest Coverage Ratio = 0.87 (Ebit TTM 14.1m / Interest Expense TTM 16.2m)
FCF Yield = 0.22% (FCF TTM 2.85m / Enterprise Value 1.31b)
FCF Margin = 1.33% (FCF TTM 2.85m / Revenue TTM 214.7m)
Net Margin = -0.98% (Net Income TTM -2.10m / Revenue TTM 214.7m)
Gross Margin = 74.76% ((Revenue TTM 214.7m - Cost of Revenue TTM 54.2m) / Revenue TTM)
Gross Margin QoQ = 76.55% (prev 74.16%)
Tobins Q-Ratio = 6.06 (Enterprise Value 1.31b / Total Assets 216.4m)
Interest Expense / Debt = 51.70% (Interest Expense 10.2m / Debt 19.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = 11.2m (EBIT 14.1m * (1 - 21.00%))
Current Ratio = 4.09 (Total Current Assets 114.5m / Total Current Liabilities 28.0m)
Debt / Equity = 0.16 (Debt 19.8m / totalStockholderEquity, last quarter 120.8m)
Debt / EBITDA = -0.19 (Net Debt -4.15m / EBITDA 21.5m)
Debt / FCF = -1.45 (Net Debt -4.15m / FCF TTM 2.85m)
Total Stockholder Equity = 110.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.97% (Net Income -2.10m / Total Assets 216.4m)
RoE = -1.90% (Net Income TTM -2.10m / Total Stockholder Equity 110.6m)
RoCE = 8.91% (EBIT 14.1m / Capital Employed (Equity 110.6m + L.T.Debt 48.2m))
RoIC = 7.05% (NOPAT 11.2m / Invested Capital 158.4m)
WACC = 8.40% (E(1.32b)/V(1.34b) * Re(8.53%) + (debt cost/tax rate unavailable))
Discount Rate = 8.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 3.27%
[DCF Debug] Terminal Value 68.29% ; FCFE base≈2.85m ; Y1≈1.87m ; Y5≈856.6k
Fair Price DCF = 0.34 (DCF Value 15.5m / Shares Outstanding 46.1m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 79.34 | EPS CAGR: 28.85% | SUE: 1.24 | # QB: 2
Revenue Correlation: 97.99 | Revenue CAGR: 18.75% | SUE: 1.79 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.06 | Chg30d=-0.004 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=0.49 | Chg30d=-0.009 | Revisions Net=+1 | Growth EPS=+65.0% | Growth Revenue=+15.6%
P/E Forward = 71.4286
P/S = 6.1286
P/B = 10.9383
Beta = 1.085
Revenue TTM = 214.7m USD
EBIT TTM = 14.1m USD
EBITDA TTM = 21.5m USD
Long Term Debt = 48.2m USD (from longTermDebt, last quarter)
Short Term Debt = 2.34m USD (from shortTermDebt, last quarter)
Debt = 19.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -4.15m USD (from netDebt column, last quarter)
Enterprise Value = 1.31b USD (1.32b + Debt 19.8m - CCE 23.9m)
Interest Coverage Ratio = 0.87 (Ebit TTM 14.1m / Interest Expense TTM 16.2m)
FCF Yield = 0.22% (FCF TTM 2.85m / Enterprise Value 1.31b)
FCF Margin = 1.33% (FCF TTM 2.85m / Revenue TTM 214.7m)
Net Margin = -0.98% (Net Income TTM -2.10m / Revenue TTM 214.7m)
Gross Margin = 74.76% ((Revenue TTM 214.7m - Cost of Revenue TTM 54.2m) / Revenue TTM)
Gross Margin QoQ = 76.55% (prev 74.16%)
Tobins Q-Ratio = 6.06 (Enterprise Value 1.31b / Total Assets 216.4m)
Interest Expense / Debt = 51.70% (Interest Expense 10.2m / Debt 19.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = 11.2m (EBIT 14.1m * (1 - 21.00%))
Current Ratio = 4.09 (Total Current Assets 114.5m / Total Current Liabilities 28.0m)
Debt / Equity = 0.16 (Debt 19.8m / totalStockholderEquity, last quarter 120.8m)
Debt / EBITDA = -0.19 (Net Debt -4.15m / EBITDA 21.5m)
Debt / FCF = -1.45 (Net Debt -4.15m / FCF TTM 2.85m)
Total Stockholder Equity = 110.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.97% (Net Income -2.10m / Total Assets 216.4m)
RoE = -1.90% (Net Income TTM -2.10m / Total Stockholder Equity 110.6m)
RoCE = 8.91% (EBIT 14.1m / Capital Employed (Equity 110.6m + L.T.Debt 48.2m))
RoIC = 7.05% (NOPAT 11.2m / Invested Capital 158.4m)
WACC = 8.40% (E(1.32b)/V(1.34b) * Re(8.53%) + (debt cost/tax rate unavailable))
Discount Rate = 8.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 3.27%
[DCF Debug] Terminal Value 68.29% ; FCFE base≈2.85m ; Y1≈1.87m ; Y5≈856.6k
Fair Price DCF = 0.34 (DCF Value 15.5m / Shares Outstanding 46.1m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: 79.34 | EPS CAGR: 28.85% | SUE: 1.24 | # QB: 2
Revenue Correlation: 97.99 | Revenue CAGR: 18.75% | SUE: 1.79 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.06 | Chg30d=-0.004 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=0.49 | Chg30d=-0.009 | Revisions Net=+1 | Growth EPS=+65.0% | Growth Revenue=+15.6%
Additional Sources for AXGN Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle